Skip to main content
. 2017 Jul 30;2017(7):CD000254. doi: 10.1002/14651858.CD000254.pub4

Comparison 2. Lutein and/or zeaxanthin versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Progression to late AMD (neovascular AMD and/or geographic atrophy 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Progression to neovascular AMD 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
3 Progression to geographic atrophy 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Progression to visual loss (loss of 3 or more lines on logMAR chart) 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Distance visual acuity: mean 3 231 Mean Difference (IV, Fixed, 95% CI) ‐0.00 [‐0.05, 0.05]
5.1 Mean visual acuity at end of study 1 72 Mean Difference (IV, Fixed, 95% CI) 0.0 [‐0.06, 0.06]
5.2 Change in visual acuity 2 159 Mean Difference (IV, Fixed, 95% CI) ‐0.01 [‐0.09, 0.08]
6 Visual Function Quality (VFQ) 1   Mean Difference (IV, Fixed, 95% CI) Totals not selected